ValiRx plc (GB:VAL) has released an update.
ValiRx PLC, a life science company specializing in cancer therapeutics and women’s health, has concluded its Evaluation project with the University of Barcelona, which focused on the development of the ‘KRAS2’ drug candidates. The initial results were promising, but the project is still at an early stage and will be returned to the university for further development without financial commitment from ValiRx. The company retains interest in future updates and potential collaborations on this and other projects.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
